human erythropoietin (rHuEpo) [1][2][3][4]. Development Background. The resistance to recombinant human and aggravation of hypertension has been documented erythropoietin (rHuEpo) therapy in haemodialysis as the most relevant side-effect of rHuEpo treatment (HD) patients has multifactorial aetiologies: erythro-with an incidence of up to 30 to 40% of treated patients poietin insufficiency, dialysis insufficiency, iron [1,2]. Risk factors for hypertension include pre-existing deficiency, and secondary hyperparathyroidism. hypertension, severe anaemia at initiation, rapid increAngiotensin-converting enzyme (ACE) inhibitors ment in haematocrit levels, high intravenous rHuEpo induce anaemia in patients with essential hypertension, doses, and the presence of native kidneys [2]. The congestive heart failure, chronic renal insufficiency, mechanisms involved in the development of hypertenand renal transplants. Data exist suggesting that ACE sion secondary to rHuEpo include loss of hypoxic inhibitors impair erythropoiesis in HD patients. dilatation and increases in blood viscosity, blood Therefore the aim of this study was to investigate the volume, activation of the renin-angiotensin system, impact of enalapril on rHuEpo requirement. endothelin levels, vascular calcium uptake, or plateletMethods. In the present prospective non-randomized dependent mitogenic action [2]. In the majority of study of 12 months, we compared the effects of enalap-haemodialysis patients, rHuEpo-induced hypertension ril and nifedipine on rHuEpo requirement in 40 hyper-is successfully controlled by water and sodium removal tensive patients receiving rHuEpo for more than 6 during dialysis, subcutaneous administration of months on maintenance haemodialysis. Twenty normo-rHuEpo, lower target haemoglobin levels and progresstensive rHuEpo-dependent patients served as a control ive attainment of this target, or conventional antihypergroup. All patients with severe hyperparathyroidism tensive therapy [1][2][3][4]. or iron deficiency were excluded.
Introduction
patients without significant untoward events [5, 6 ] .
ACE inhibitors are widely used in the treatment of Anaemia, a consistent clinical feature of end-stage hypertension, left ventricular dysfunction, diabetic renal disease, is efficiently treated with recombinant nephropathy, and renal post-transplant erythrocytosis, and in preventing the progression of established renal patients with hypertension treated with enalapril or means±standard deviation. Univariate analysis was used to nifedipine, compared to normotensive patients treated identify differences among the three group. All P values were with rHuEpo who served as a control group for 12 two-tailed and a P value ∏0.05 was considered statistically months of follow-up.
significant.
Subjects and methods Results
We evaluated patients from five haemodialysis centres who Patient characteristics and laboratory data are sumhad been on maintenance haemodialysis for more than 6 marized in Tables 1 and 2 . The majority of patients in months and who were treated with antihypertensive drugs all groups had ESRD secondary to diabetic nephroand rHuEpo for more than two months with a haemoglobin pathy, hypertensive nephropathy, or glomerular concentration Á10 g/dl.
nephropathy ( Table 1) . One patient in the enalapril
We excluded all patients with folate or vitamin B 12 defigroup was omitted due to cough attributed to ACE ciency, serum aluminium >40 mg/l, serum ferritin <200 mg/l, inhibitor therapy, and two patients in the nifedipine intact parathyroid hormone (iPTH ) >300 pg/ml, active bleeding lesions, haematological diseases, active untreated group were excluded because of pitting oedema of the infections, malignancies or other causes of inflammation, lower extremities attributed to nifedipine in the first and those taking bone-marrow suppression medications. All case and a severe inflammatory syndrome in the patients were matched with respect to age, sex, subjacent second. Two patients in the control group received renal disease, duration on HD, dialysis parameters, intact renal grafts and were also excluded.
parathyroid hormone levels, haemoglobin concentrations,
Fifteen patients were treated with 20 mg of enalapril;
iron status, and rHuEpo dose before starting this study.
four patients with 10 mg of enalapril, and 18 patients Forty hypertensive patients fulfilled these criteria, and 20 were on 40 mg of nifedipine. Four patients in the rHuEpo-dependent patients without hypertension served as enalapril group and five patients in the nifedipine a control group. Patients were divided into one of three group also received atenolol to maintain blood pressure classifications based on treatment regimen: those who had enalapril plus rHuEpo (n=20, enalapril group); nifedipine within the normal range.
plus rHuEpo (n=20, nifedipine group); and rHuEpo (n= There was no statistically significant difference 20, control group ). The initial doses of enalapril and slow-among the three groups in terms of age, sex, duration release nifedipine were 5 and 20 mg/day respectively. The on haemodialysis, blood pressure, Kt/V, PCR, serum doses of enalapril and nifedipine were increased to adequately albumin, iPTH, iron status, absolute reticulocyte control the (BP <140/90 mmHg). When maximal doses count, or haemoglobin values. Average haemoglobin (20 mg/day for enalapril or 40 mg/day for nifedipine) of concentrations were 10.6±0.4 g/dl, 10.7±0.2 g/dl, initial medications were reached, atenolol was added in order and 10.8±0.3 g/dl before and 10.5±0.3 g/dl, to control the high blood pressure more adequately.
Intravenous iron infusion (average dosage 50-100 mg/week) was used to maintain serum ferritin Á400 mg/l 10.4±0.2 g/dl, and 10.3±0.2 g/dl at 1 year in the However, there were no statistically significant differences between the nifedipine group and control group enalapril, nifedipine, and control groups respectively. Figure 1 compares the mean weekly rHuEpo dose (P=NS).
The mean monthly individual intravenous ferric subcutaneously administered to the three groups. To maintain a similar haemoglobin level, the enalapril hydroxide polymaltose dose was 212±61 mg in the enalapril group, 194±53 mg in the nifedipine group, group received 84±14 IU/kg/week before and 138±10 U/kg/week at 1 year (P<0.0001 vs before), 86±7 and 197±47 mg in the control group. Again, there were no statistically significant differences among the U/kg/week before and 77±5 U/kg/week at 1 year in the nifedipine group (P<0.0001 vs enalapril at 1 year), three groups (P=NS ). None of the patients received transfusions during the study. and 79±11 U/kg/week before and 80±9 U/kg/week in the control group (P<0.0001 vs enalapril at 1 year).
Discussion
In this study we have shown that high-dose enalapril can lead to substantial and sustained increase in rHuEpo requirement of haemodialysis populations. The mean rHuEpo dose increased significantly after 1 year of treatment with ACE inhibitors (P<0.0001). To maintain the same level of haemoglobin, the group of patients treated with enalapril needed a higher dose of rHuEpo than the group of patients treated with nifedipine and the control group over the 1-year study period (P<0.0001). rHuEpo requirement did not significantly differ between the nifedipine group and control group. Further, the mean rHuEpo dose in enalapril group returned to the baseline value 4 months after discontinuing enalapril (results not shown).
There are many causes for rHuEpo resistance in HD patients, such as functional iron deficiency, secondary hyperparathyroidism, aluminium overload, dialysis insufficiency, blood loss, or inflammatory syndrome [5, 6 ] . In our study we excluded all patients with any one of these conditions. Good iron status was assessed by transferrin saturation >25% and serum ferritin >400 mg/l, aluminium overload was avoided by using calcium carbonate as the only phosphate chelator, and adequate dialysis was defined by Kt/V >1, PCR >1, and serum albumin >35 g/l. In addition, there was no statistical differences regarding iPTH levels, iron status parameters (hypochromic RBC not measured ), haemoglobin levels, and indicators of adequate dialysis The target haemoglobin level for anaemia treatment ril enhances the plasma level of Ac-SKDP and/or lowers renal and extrarenal endogenous erythropoietin was 10-11 g/dl which is the case for the majority of European studies [4, 30] , while in the USA the upper production; explaining the refractoriness to rHuEpo therapy. target haemoglobin limit has been extended to more than 12 g/dl [2] . Adequate dialysis parameters may
We conclude that high-dose enalapril increases rHuEpo requirement and should be reserved for HD improve renal failure anaemia and consequently reduce rHuEpo need in HD patients, explaining the relatively patients with high blood pressure resistant to other antihypertensive medications or those with congestive low rHuEpo dose of the control and nifedipine groups, similar to that reported by others [31] . heart failure, unless there are specific indications to the contrary. We acknowledge that this study has several limitations. First, we studied a relatively small number of patients without randomization, but all patients were
